We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Alterity Therapeutics was incorporated in Melbourne, Australia in 1997 as Prana Biotechnology and has offices in Melbourne, Australia, and San Francisco, USA. The Company listed on the Australian Securities Exchange in 2000 and listed on the NASDAQ in 2002.
The company operates under the ticker codes ASX: ATH and NASDAQ: ATHE
Board of Directors
Mr. Kempler is a qualified psychologist with extensive experience in investment and business developmentand has been responsible for the implementation of our strategic plan and the commercialisation of our technology. Mr. Kempler holds a B.Sc degree in science from Monash University, Grad. Dip. App. Soc. Psych. degree from Swinburne University, and is on the Monash Institute of Cognitive and Clinical Neurosciences (MICCN) Industry Advisory Board. Mr Kempler was appointed as a Non-Executive Chairman of Opthea Limited, an ASX listed drug development company developing innovative, biologics-based therapies for the treatment of eye diseases, on November 30, 2015.
Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte.
Mr. Gozlan is currently a Director of Opthea Limited, an ASX listed drug development company and AusBiotech, which is the Australian Biotechnology Industry body and a number of private biotechnology companies in the USA. He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne specializing in neurodegenerative diseases.
For over 13 years until the end of August 2014, Mr. Marks was a Director of investment bank Peregrine Corporate Ltd, and is currently Chairman of Newburyport Partners, a boutique corporate and capital markets advisory firm specializing in advising small to mid-cap companies.
Mr Marks is currently a non-executive Director of Electriq Global Ltd, and also currently serves as Director of Noxopharm Ltd, an ASX listed biotechnology company, and Noxopharm subsidiary, Nyrada Inc.
Mr. Meltzer has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government licensed Innovation Investment Fund. Mr. Meltzer is also a director on the board of the Australian-Israel Chamber of Commerce and is Chairman of Independence Australia (previously Paraquad).
He is Chairman of the Audit Committee and member of the Remuneration Committee.